臨床ゲノミクス市場：製品・サービス別、技術別、用途別、感染症、エンドユーザー別、地域別

臨床ゲノミクス市場は、2025年には125億米ドルと推定され、2032年には263億米ドルに達すると予測され、2025～2032年までの年間平均成長率（CAGR）は11.2%で成長する見込みです。

世界の臨床ゲノミクス市場は、ヘルスケア産業において急速に発展しているセグメントであり、個別化医療と精密治療の産業情勢を根本的に変革しています。臨床ゲノミクスは、医療上の意思決定、疾病診断、治療選択、予後判定に情報を提供するために、個人の遺伝子構成を包括的に分析することを包含します。この学際的なセグメントは、ゲノム研究と臨床のギャップを埋め、ヘルスケアプロバイダが患者固有の遺伝子プロファイルに基づいてオーダーメイドの医療介入を提供できるようにします。

この市場には、全ゲノムシーケンス、標的遺伝子パネル、薬理ゲノミクス検査、腫瘍ゲノミクス、希少疾患診断など、広範な技術、サービス、アプリケーションが含まれます。世界中のヘルスケアシステムが精密医療のアプローチをますます採用するようになる中、臨床ゲノミクスは医薬品開発、バイオマーカー探索、治療最適化のイノベーションを推進する基盤技術として台頭してきました。先進的シーケンス技術、人工知能、ビッグデータ分析の統合により、ゲノム検査へのアクセス性、精度、費用対効果が大幅に向上し、世界の多様な医療環境と患者集団における日常的な臨床実施がより現実的なものとなっています。

市場力学

世界の臨床ゲノミクス市場は、成長軌道を加速し続けるいくつかの強力な促進要因に後押しされています。遺伝性疾患、がん、希少疾患の世界の蔓延は、正確な診断・治療ソリューションに対する大きな需要を生み出し、臨床ゲノミクスはヘルスケアプロバイダにとって不可欠なツールと位置づけられています。次世代シークエンシング（NGS）の技術的進歩、ゲノム検査コストの低下、データ解釈能力の向上により、ゲノム分析はより身近で実用的なものとなり、広く臨床に採用されるようになりました。国家ゲノムプロジェクトやプレシジョンメディシンプログラムなど、ゲノム研究に対する政府の取り組みや多額の投資は、市場拡大に大きな勢いを与えています。

個別化医療の利点に関するヘルスケア専門家や患者の意識の高まりは、世界の医療支出の増加と相まって、市場成長をさらに後押ししています。しかし、地域によって異なる複雑な規制の枠組みが市場参入企業にコンプライアンス上の課題をもたらすなど、市場は顕著な抑制要因に直面しています。初期インフラコストの高さ、熟練したゲノミクス専門家の不足、データのプライバシーとセキュリティに関する懸念は、特に新興経済諸国において開発の大きな障壁となっています。遺伝子検査をめぐる倫理的配慮や潜在的な差別問題も、市場導入を制限しています。最適化された薬剤の選択と投与戦略を可能にする薬理ゲノミクスの応用拡大や、データ分析と解釈を強化するための人工知能と機械学習技術の統合が進むことにより、大きなビジネス機会が存在します。新興市場には未開拓の成長の可能性がある一方、ポイントオブケア・ゲノム検査とリキッドバイオプシー技術における継続的な技術革新は、市場拡大と患者の転帰改善のための有望な道筋を記載しています。

本調査の主要特徴

• 本レポートでは、世界の臨床ゲノミクス市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模（10億米ドル）と年間平均成長率（CAGR%）を掲載しています。
• さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案のマトリックスについて説明しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域による展望、主要企業が採用する競合戦略などに関する重要な考察も提供しています。
• 企業ハイライト、製品ポートフォリオ、主要なハイライト、財務実績、戦略などのパラメータに基づいて、世界の臨床ゲノミクス市場の主要企業プロファイルを掲載しています。
• 本レポートから洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• 臨床ゲノミクスの世界市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この産業の様々な利害関係者を対象としています。
• 利害関係者は、世界の臨床ゲノミクス市場を分析する際に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー

第3章 市場力学、規制、動向分析

• 市場力学
• 促進要因
• 抑制要因
• 機会
• 影響分析
• 規制シナリオ
• 製品の発売/承認
• PEST分析
• ポーター分析
• 合併と買収のシナリオ
• 産業動向

第4章 世界の臨床ゲノミクス市場、製品・サービス別、2020～2032年

• イントロダクション
• 機器またはシステム
• シーケンサー
• 消耗品
• 試薬とキット
• ソフトウェアとサービス
• データ分析と解釈

第5章 世界の臨床ゲノミクス市場、技術別、2020～2032年

• イントロダクション
• 次世代シーケンス（NGS）
• ポリメラーゼ連鎖反応（PCR）
• マイクロアレイ
• サンガーシーケンス
• その他の技術（例：FISH、核型分析）

第6章 世界の臨床ゲノミクス市場、用途別、2020～2032年

• イントロダクション
• 腫瘍学
• がんの診断と予後
• 感染症
• 病原体の同定と特性評価（細菌、ウイルス、真菌、寄生虫）
• 遺伝性疾患
• 新生児スクリーニング
• 心血管疾患
• 遺伝性心筋症検査
• 神経疾患
• 神経変性疾患検査（例：アルツハイマー病、ハンチントン病）
• その他の応用（薬理ゲノム学など）

第7章 世界の臨床ゲノミクス市場、エンドユーザー別、2020～2032年

• イントロダクション
• 病院とクリニック
• 診断ラボ
• 製薬とバイオテクノロジー企業
• その他（学術研究機関等）

第8章 世界の臨床ゲノミクス市場、地域別、2020～2032年

• イントロダクション
• 北米
  • 米国
  • カナダ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
  • メキシコ
  • その他のラテンアメリカ
• 欧州
  • ドイツ
  • 英国
  • スペイン
  • フランス
  • イタリア
  • ロシア
  • その他の欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • ASEAN諸国
  • その他のアジア太平洋
• 中東
  • GCC諸国
  • イスラエル
  • その他の中東
• アフリカ
  • 南アフリカ
  • 北アフリカ
  • 中央アフリカ

第9章 競合情勢

• Illumina Inc
• Thermo Fisher Scientific Inc
• F Hoffmann-La Roche Ltd
• QIAGEN NV
• Agilent Technologies Inc
• BGI Genomics
• PerkinElmer Inc
• Bio-Rad Laboratories Inc
• Danaher Corporation（Cepheid, IDT）
• Oxford Nanopore Technologies
• Pacific Biosciences
• Myriad Genetics Inc
• Guardant Health
• Eurofins Scientific
• GE HealthCare

第10章 アナリストの推奨事項

• 機会
• 一貫型機会マップ

第11章 参考文献と調査手法

• 参考文献
• 調査手法
• 出版社について

Clinical Genomics Market is estimated to be valued at USD 12.5 Bn in 2025 and is expected to reach USD 26.3 Bn by 2032, growing at a compound annual growth rate (CAGR) of 11.2% from 2025 to 2032.

The Global Clinical Genomics Market represents a rapidly evolving sector within the healthcare industry, fundamentally transforming the landscape of personalized medicine and precision therapeutics. Clinical genomics encompasses the comprehensive analysis of an individual's genetic makeup to inform medical decision-making, disease diagnosis, treatment selection, and prognosis determination. This interdisciplinary field bridges the gap between genomic research and clinical practice, enabling healthcare providers to deliver tailored medical interventions based on patients' unique genetic profiles.

The market encompasses a broad spectrum of technologies, services, and applications including whole genome sequencing, targeted gene panels, pharmacogenomics testing, oncology genomics, and rare disease diagnostics. As healthcare systems worldwide increasingly adopt precision medicine approaches, clinical genomics has emerged as a cornerstone technology driving innovation in drug development, biomarker discovery, and therapeutic optimization. The integration of advanced sequencing technologies, artificial intelligence, and big data analytics has significantly enhanced the accessibility, accuracy, and cost-effectiveness of genomic testing, making it more viable for routine clinical implementation across diverse healthcare settings and patient populations globally.

Market Dynamics

The Global Clinical Genomics Market is propelled by several compelling drivers that continue to accelerate its growth trajectory. The increasing prevalence of genetic disorders, cancer, and rare diseases worldwide has created substantial demand for precise diagnostic and therapeutic solutions, positioning clinical genomics as an indispensable tool for healthcare providers. Technological advancements in next-generation sequencing (NGS), declining costs of genomic testing, and improved data interpretation capabilities have made genomic analysis more accessible and practical for widespread clinical adoption. Government initiatives and substantial investments in genomics research, including national genome projects and precision medicine programs, have provided significant momentum to market expansion.

The growing awareness among healthcare professionals and patients about the benefits of personalized medicine, coupled with increasing healthcare expenditure globally, further drives market growth. However, the market faces notable restraints including complex regulatory frameworks that vary across different regions, creating compliance challenges for market participants. High initial infrastructure costs, shortage of skilled genomics professionals, and concerns regarding data privacy and security pose significant barriers to market penetration, particularly in developing economies. Ethical considerations surrounding genetic testing and potential discrimination issues also limit market adoption. Nevertheless, substantial opportunities exist through expanding applications in pharmacogenomics, which enables optimized drug selection and dosing strategies, and the growing integration of artificial intelligence and machine learning technologies for enhanced data analysis and interpretation. Emerging markets present untapped potential for growth, while continuous innovation in point-of-care genomic testing and liquid biopsy technologies offers promising avenues for market expansion and improved patient outcomes.

Key Features of the Study

• This report provides an in-depth analysis of the global clinical genomics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global clinical genomics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Illumina Inc, Thermo Fisher Scientific Inc, F Hoffmann-La Roche Ltd, QIAGEN NV, Agilent Technologies Inc, BGI Genomics, PerkinElmer Inc, Bio-Rad Laboratories Inc, Danaher Corporation (Cepheid, IDT), Oxford Nanopore Technologies, Pacific Biosciences, Myriad Genetics Inc, Guardant Health, Eurofins Scientific, and GE HealthCare.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global clinical genomics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global clinical genomics market.

Market Segmentation

• Product and Service Insights (Revenue, USD Bn, 2020 - 2032)
  • Instruments or Systems
  • Sequencers
  • PCR Systems
  • Microarray Scanners
  • Automated Liquid Handlers
  • Other Genomic Analyzers
  • Consumables
  • Reagents and Kits
  • Sequencing Chips and Flow Cells
  • Sample Collection Kits
  • Others (Probes and Primers)
  • Software and Services
  • Data Analysis and Interpretation
  • Sequencing Services
  • Others (Clinical Laboratory Services, etc)
• Technology Insights (Revenue, USD Bn, 2020 - 2032)
  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Microarray
  • Sanger Sequencing
  • Other Technologies (e.g., FISH, Karyotyping)
• Application Insights (Revenue, USD Bn, 2020 - 2032)
  • Oncology
  • Cancer Diagnosis and Prognosis
  • Therapy Selection and Companion Diagnostics
  • Hereditary Cancer Risk Assessment
  • Minimal Residual Disease (MRD) Monitoring
  • Liquid Biopsy Analysis
  • Infectious Diseases
  • Pathogen Identification and Characterization (Bacterial, Viral, Fungal, Parasitic)
  • Outbreak Surveillance and Strain Typing
  • Antimicrobial Resistance Testing
  • Genetic Disorders
  • Newborn Screening
  • Carrier Screening
  • Prenatal Diagnosis
  • Preimplantation Genetic Testing
  • Diagnosis of Rare and Inherited Diseases
  • Cardiovascular Diseases
  • Inherited Cardiomyopathies Testing
  • Arrhythmia Genetic Testing (e.g., Long QT Syndrome)
  • Aortopathies Genetic Testing (e.g., Marfan Syndrome)
  • Genetic Hypercholesterolemias Testing
  • Neurological Disorders
  • Neurodegenerative Disease Testing (e.g., Alzheimer's, Huntington's)
  • Neuromuscular Disorder Testing (e.g., Duchenne Muscular Dystrophy)
  • Epilepsy Genetic Testing
  • Neurodevelopmental Disorder Testing
  • Other Applications (Pharmacogenomics, etc.)
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Others (Academic and Research Institutes, etc.)
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Player Insights
  • Illumina Inc
  • Thermo Fisher Scientific Inc
  • F Hoffmann-La Roche Ltd
  • QIAGEN NV
  • Agilent Technologies Inc
  • BGI Genomics
  • PerkinElmer Inc
  • Bio-Rad Laboratories Inc
  • Danaher Corporation (Cepheid, IDT)
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Myriad Genetics Inc
  • Guardant Health
  • Eurofins Scientific
  • GE HealthCare

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Clinical Genomics Market, By Product and Service
  • Global Clinical Genomics Market, By Technology
  • Global Clinical Genomics Market, By Application
  • Global Clinical Genomics Market, By End User
  • Global Clinical Genomics Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Clinical Genomics Market, By Product and Service, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Instruments or Systems
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Sequencers
  • PCR Systems
  • Microarray Scanners
  • Automated Liquid Handlers
  • Other Genomic Analyzers
• Consumables
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Reagents and Kits
  • Sequencing Chips and Flow Cells
  • Sample Collection Kits
  • Others (Probes and Primers)
• Software and Services
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Data Analysis and Interpretation
  • Sequencing Services
  • Others (Clinical Laboratory Services, etc.)

5. Global Clinical Genomics Market, By Technology, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Next-Generation Sequencing (NGS)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Polymerase Chain Reaction (PCR)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Microarray
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Sanger Sequencing
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Other Technologies (e.g., FISH, Karyotyping)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Clinical Genomics Market, By Application, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Cancer Diagnosis and Prognosis
  • Therapy Selection and Companion Diagnostics
  • Hereditary Cancer Risk Assessment
  • Minimal Residual Disease (MRD) Monitoring
  • Liquid Biopsy Analysis
• Infectious Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pathogen Identification and Characterization (Bacterial, Viral, Fungal, Parasitic)
  • Outbreak Surveillance and Strain Typing
  • Antimicrobial Resistance Testing
• Genetic Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Newborn Screening
  • Carrier Screening
  • Prenatal Diagnosis
  • Preimplantation Genetic Testing
  • Diagnosis of Rare and Inherited Diseases
• Cardiovascular Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Inherited Cardiomyopathies Testing
  • Arrhythmia Genetic Testing (e.g., Long QT Syndrome)
  • Aortopathies Genetic Testing (e.g., Marfan Syndrome)
  • Genetic Hypercholesterolemia's Testing
• Neurological Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Neurodegenerative Disease Testing (e.g., Alzheimer's, Huntington's)
  • Neuromuscular Disorder Testing (e.g., Duchenne Muscular Dystrophy)
  • Epilepsy Genetic Testing
  • Neurodevelopmental Disorder Testing
• Other Applications (Pharmacogenomics, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Clinical Genomics Market, By End User, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Hospitals and Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Diagnostic Laboratories
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pharmaceutical and Biotechnology Companies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others (Academic and Research Institutes, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Clinical Genomics Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Product and Service, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Product and Service, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Product and Service, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Product and Service, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Product and Service, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Product and Service, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Illumina Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Thermo Fisher Scientific Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• F Hoffmann-La Roche Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• QIAGEN NV
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Agilent Technologies Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• BGI Genomics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• PerkinElmer Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bio-Rad Laboratories Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Danaher Corporation (Cepheid, IDT)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Oxford Nanopore Technologies
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pacific Biosciences
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Myriad Genetics Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Guardant Health
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eurofins Scientific
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GE HealthCare
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us